Journal of Biosciences

, Volume 26, Issue 3, pp 383–390

Orally active insulin mimics: where do we stand now?

  • M. Balasubramanyam
  • V. Mohan
Review

DOI: 10.1007/BF02703748

Cite this article as:
Balasubramanyam, M. & Mohan, V. J Biosci (2001) 26: 383. doi:10.1007/BF02703748

Abstract

The war against diabetes through the development of new drugs is an ongoing continuous process to counter the alarming global increase in the prevalence of diabetes and its complications, particularly in developing countries like India. Unfortunately, the speed with which our knowledge of diabetes and its effects is expanding is not matched by the availability of new drugs. Following the identification of the insulin receptor (IR), its intrinsic kinase activity and molecular cloning, many studies have looked at IR as an ideal drug target. This review summarizes in brief the latest advancements in this field with particular reference to the current situation in respect of the development of orally active insulin mimetics in the treatment of type 2 diabetes.

Keywords

Insulin mimeticinsulin receptor tyrosine kinasePI 3-kinasevanadium

Abbreviations used

EGFR

Epidermal growth factor receptor

GPI

glycosyl-phosphoinositol

IGF1R

insulin growth factor-1 receptor

IR

insulin receptor

IRS

insulin receptor substrate

IRTK

insulin receptor tyrosine kinase

OBA

2-(oxalylamino)-benzoic acid

pVs

peroxovanadiums

PI 3-kinase

phosphatidylinositol 3-kinase

PIG

phosphoinositolglycan

PTPases

phosphotyrosine phosphatase

PDGFR

platelet-derived growth factor receptor

Copyright information

© Indian Academy of Sciences 2001

Authors and Affiliations

  • M. Balasubramanyam
    • 1
  • V. Mohan
    • 1
  1. 1.Madras Diabetes Research Foundation (MDRF)Gopalapuram, ChennaiIndia